>

Uwe Rohrhoff - Perrigo Company President CEO, Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>PRG</div>
PRGO -- USA Stock  

Last Earning Anouncement Date: December 31, 2015  

  CEO
Mr. Uwe Rohrhoff serves as President, Chief Executive Officer, Director of Perrigo Company Public Limited Company effective January 15, 2018. Prior to joining Perrigo, Mr. Roehrhoff served as Chief Executive Officer of Gerresheimer AG, a leading global manufacturer of pharmaceutical packaging products and medical devices for storage, dosage and safe administration of drugs. He began his career with Gerresheimer AG in 1991 and steadily advanced to serve in a number of key leadership roles in Europe and North America, including leading the American subsidiary Gerresheimer Glass Inc. from 2001 until 2010. He served as an executive board member from 2003 until 2017, responsible for two of the companys three business units, and CEO of Gerresheimer AG from 2010 until his retirement in August 2017. Since May 2017, Mr. Roehrhoff has served as deputy chairman of KlcknerCo SE. Mr. Roehrhoff also served as Audit Committee Chairman on the Board of Directors of Catalent, Inc. from February 2017 until February 2018.
Age: 54  CEO Since 2018      
353 1 709 4000  http://www.perrigo.com

Management Efficiency

The company has return on total asset (ROA) of 2.19 % which means that it generated profit of $2.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.32 % meaning that it created $4.32 on every $100 dollars invested by stockholders.
The company currently holds 3.5 B in liabilities with Debt to Equity (D/E) ratio of 60.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 2.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 6 records

CEO Since

Leonard SchleiferRegeneron Pharmaceuticals
1994
Juan AlaixZoetis
2012
Kristin PeckZoetis
2020
M RamanaDr Reddys Laboratories Ltd
2018
William NieburOrigin Agritech Limited
2016
MARC KIKUCHIDr Reddys Laboratories Ltd
2019

Company Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, PresidentView
Gary Cohen, Independent DirectorView
Arthur Shannon, IR Contact OfficerView
Ronald Winowiecki, Acting CFOView
Svend Andersen, Executive Vice President and President - Consumer Healthcare InternationalView
Judy Brown, CFO and Executive VPView
Laurie Brlas, Independent DirectorView
Donal OConnor, Independent DirectorView
James Michaud, Chief Human Resource Officer, Executive Vice PresidentView
Louis Yu, Executive Vice President - Global QualityView
John Wesolowski, Executive Vice President and Presidentident - RXView
Theodore Samuelsto, Independent DirectorView
Scott Jamison, Executive Vice President General Manager - NutritionalsView
Ellen Hoffing, Independent DirectorView
Marc Coucke, Executive Vice President General Manager - Omega Pharma BusinessView
Adriana Karaboutis, Independent DirectorView
Michael Jandernoa, Independent DirectorView
Paul Weninger, Executive Vice President - Global Quality OperationsView
Thomas Farrington, Senior Vice President CIOView
Herman Morris, Independent DirectorView
Jeffrey Needham, Executive Vice President General Manager - Consumer HealthcareView
Todd Kingma, Executive VP, General Counsel and SecretaryView
Rolf Classon, Independent DirectorView
Raymond Silcock, CFOView
Shlomo Yanai, Independent Director NomineeView
Jatin Shah, Senior Vice President Chief Scientific OfficerView
Michael Stewart, Senior Vice President - Global Human ResourcesView
Jeffrey Kindler, Independent DirectorView
Jacqualyn Fouse, Independent DirectorView
Grainne Quinn, Executive Vice President Chief Medical OfficerView
Theodore Samuels, Independent DirectorView
Geoffrey Parker, Independent DirectorView
Murray Kessler, President CEO, DirectorView
Sharon Kochan, Executive VP and General Manager of InternationalView
Gary Kunkle, Lead Independent DirectorView
Joseph Papa, Chairman and CEOView
Marry Brlas, Independent Chairman of the BoardView
Bradley Alford, Independent DirectorView
Jeffrey Smith, Independent DirectorView
Bradley Joseph, IR Contact OfficerView
James Dillard, Executive Vice President Chief Scientific OfficerView
Douglas Boothe, Executive Vice President General Manager - Rx PharmaceuticalsView
Ronald Janish, Executive Vice President - Global Operations and Supply ChainView
Uwe Rohrhoff, President CEO, DirectorView

Stock Performance Indicators

Did you try this?

Run Pattern Recognition Now

   

Pattern Recognition

Use different Pattern Recognition models to time the market across multiple global exchanges
All  Next Launch Module

Currently Active Assets on Macroaxis

GM   
Purchased over 100 shares of
a day ago
Traded for 30.71
ECA   
Purchased over 500 shares of
a day ago
Traded for 3.54
GM   
Purchased over 100 shares of
a day ago
Traded for 30.71
WD   
Purchased over 40 shares of
a day ago
Traded for 66.38
DD   
Purchased over 70 shares of
a day ago
Traded for 43.18
Please check Your Equity Center. Please also try Idea Breakdown module to analyze constituents of all macroaxis ideas. macroaxis investment ideas are predefined, sector-focused investing themes.